Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
12 02 2020
Historique:
received: 11 12 2019
revised: 30 01 2020
accepted: 08 02 2020
entrez: 16 2 2020
pubmed: 16 2 2020
medline: 30 3 2021
Statut: epublish

Résumé

Human prion diseases are classified into sporadic, genetic, and acquired forms. Within this last group, iatrogenic Creutzfeldt-Jakob disease (iCJD) is caused by human-to-human transmission through surgical and medical procedures. After reaching an incidence peak in the 1990s, it is believed that the iCJD historical period is probably coming to an end, thanks to lessons learnt from past infection sources that promoted new prion prevention and decontamination protocols. At this point, we sought to characterise the biomarker profile of iCJD and compare it to that of sporadic CJD (sCJD) for determining the value of available diagnostic tools in promptly recognising iCJD cases. To that end, we collected 23 iCJD samples from seven national CJD surveillance centres and analysed the electroencephalogram and neuroimaging data together with a panel of seven CSF biomarkers: 14-3-3, total tau, phosphorylated/total tau ratio, alpha-synuclein, neurofilament light, YKL-40, and real-time quaking induced conversion of prion protein. Using the cut-off values established for sCJD, we found the sensitivities of these biomarkers for iCJD to be similar to those described for sCJD. Given the limited relevant information on this issue to date, the present study validates the use of current sCJD biomarkers for the diagnosis of future iCJD cases.

Identifiants

pubmed: 32059611
pii: biom10020290
doi: 10.3390/biom10020290
pmc: PMC7072321
pii:
doi:

Substances chimiques

Biomarkers 0
Prion Proteins 0
Human Growth Hormone 12629-01-5
Methionine AE28F7PNPL

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : CP/00041
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI19/00144
Pays : International
Organisme : Robert Koch Institute
ID : 1369-341
Pays : International
Organisme : Interreg V-A España-Francia-Andorra
ID : POCTEFA 2014-2020
Pays : International
Organisme : NHMRC Practitioner Fellowship
ID : APP1105784
Pays : International

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

BMC Neurol. 2011 Oct 04;11:120
pubmed: 21970675
BMC Neurol. 2012 Dec 05;12:153
pubmed: 23216655
Hum Genet. 1999 Sep;105(3):244-52
pubmed: 10987652
Brain. 2009 Oct;132(Pt 10):2659-68
pubmed: 19773352
Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20
pubmed: 26783546
JAMA Neurol. 2019 Jun 17;:
pubmed: 31206160
Alzheimers Dement (Amst). 2018 Jul 07;10:461-470
pubmed: 30294658
Neurology. 2011 May 17;76(20):1711-9
pubmed: 21471469
Dement Geriatr Cogn Disord. 2017;43(1-2):71-80
pubmed: 28056460
Acta Neuropathol. 2017 Apr;133(4):559-578
pubmed: 28205010
Alzheimers Res Ther. 2018 Jan 11;10(1):3
pubmed: 29368621
Neurology. 2009 Jun 9;72(23):1994-2001
pubmed: 19506221
Mol Neurobiol. 2016 Apr;53(3):1896-1904
pubmed: 25823511
Neurosurg Focus. 2016 Jul;41(1):E10
pubmed: 27364252
J Alzheimers Dis. 2015;50(3):873-86
pubmed: 26836182
Sci Rep. 2019 Feb 12;9(1):1836
pubmed: 30755683
J Clin Neurosci. 2000 May;7(3):203-8
pubmed: 10833616
Sci Rep. 2016 Dec 08;6:38737
pubmed: 27929120
Br Med Bull. 2003;66:241-54
pubmed: 14522862
Clin Neurophysiol. 2004 Nov;115(11):2467-78
pubmed: 15465434
J Korean Med Sci. 2011 Nov;26(11):1515-7
pubmed: 22065911
Brain. 2004 Oct;127(Pt 10):2348-59
pubmed: 15361416
PLoS One. 2015 Aug 13;10(8):e0135458
pubmed: 26270969
Br Med Bull. 2003;66:213-39
pubmed: 14522861
Mol Neurobiol. 2016 May;53(4):2189-99
pubmed: 25947081
Alzheimers Dement. 2016 May;12(5):577-89
pubmed: 26718584
Neuroscience. 2016 May 13;322:398-407
pubmed: 26940479
Neurology. 2018 Jul 24;91(4):e331-e338
pubmed: 29934424
Mol Neurodegener. 2017 Nov 10;12(1):83
pubmed: 29126445
Neurology. 2006 Aug 22;67(4):637-43
pubmed: 16924018
Neurology. 2007 Jul 24;69(4):360-7
pubmed: 17646628
Alzheimers Dement. 2018 Jun;14(6):751-763
pubmed: 29391125
Nat Protoc. 2016 Nov;11(11):2233-2242
pubmed: 27735933
Mol Neurobiol. 2019 May;56(5):3476-3483
pubmed: 30136097
Ann Neurol. 1998 Jan;43(1):32-40
pubmed: 9450766
Alzheimers Dement. 2017 Jun;13(6):710-719
pubmed: 27870938
Br Med Bull. 2003;66:121-30
pubmed: 14522854
J Clin Neurosci. 2019 Feb;60:124-127
pubmed: 30309804
J Neurol. 2019 Dec;266(12):3136-3143
pubmed: 31541342
Handb Clin Neurol. 2018;153:357-370
pubmed: 29887145
Brain. 2007 May;130(Pt 5):1350-9
pubmed: 17472986
Emerg Infect Dis. 2012 Jun;18(6):901-7
pubmed: 22607808
Arq Neuropsiquiatr. 2002 Jun;60(2-B):458-61
pubmed: 12131950
J Neurol. 2009 Mar;256(3):355-63
pubmed: 19159063
Neurology. 2006 Aug 8;67(3):389-93
pubmed: 16855204
Brain Pathol. 2019 Mar;29(2):248-262
pubmed: 30588682
J Epidemiol. 2011;21(4):255-62
pubmed: 21628843
Acta Neuropathol Commun. 2015 Jun 25;3:37
pubmed: 26108478
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):87-90
pubmed: 22407223
Neurology. 2000 Sep 26;55(6):811-5
pubmed: 10994001
Handb Clin Neurol. 2018;153:207-218
pubmed: 29887137
Brain. 2015 Nov;138(Pt 11):3386-99
pubmed: 26268531
Br Med Bull. 2003;66:255-65
pubmed: 14522863
Neurology. 2000 Oct 24;55(8):1075-81
pubmed: 11071481
Eur J Neurol. 2017 Nov;24(11):1326-e77
pubmed: 28816001
Arch Neurol. 2006 Feb;63(2):288-90
pubmed: 16476821

Auteurs

Franc Llorens (F)

Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.

Anna Villar-Piqué (A)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.

Peter Hermann (P)

Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.

Matthias Schmitz (M)

Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.

Olga Calero (O)

Chronic Disease Programme (UFIEC)-CROSADIS, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.

Christiane Stehmann (C)

Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.

Shannon Sarros (S)

Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.

Fabio Moda (F)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5 and Neuropathology, 20133 Milan, Italy.

Isidre Ferrer (I)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.
Department of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, 08907 Llobregat, Spain.

Anna Poleggi (A)

Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.

Maurizio Pocchiari (M)

Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.

Marcella Catania (M)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5 and Neuropathology, 20133 Milan, Italy.

Sigrid Klotz (S)

Institute of Neurology, Medical University of Vienna, Vienna 1097, Austria.

Carl O'Regan (C)

Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.

Francesca Brett (F)

Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.

Josephine Heffernan (J)

Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.

Anna Ladogana (A)

Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.

Steven J Collins (SJ)

Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.
Department of Medicine (RMH), The University of Melbourne, Melbourne 3050, Australia.

Miguel Calero (M)

Chronic Disease Programme (UFIEC)-CROSADIS, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.

Gabor G Kovacs (GG)

Institute of Neurology, Medical University of Vienna, Vienna 1097, Austria.
Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto On, M5T 0S8, Canada.
Laboratory Medicine Program, University Health Network, Toronto ON, M5G 2C4, Canada.

Inga Zerr (I)

Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH